Global Liver Institute
Liver Health Policy
GLOBAL LIVER INSTITUTE
Policy Agenda
GLI advocates for the elevation of liver health to its rightful place on the global public health agenda commensurate with its prevalence and impact.
GLI engages with
U.S. Federal Agencies: CMS, CDC, NIH, NIDDK, VA, & more
U.S. Congress
Global Health Agencies: WHO, EMA, & more
Priority Initiatives
COVID-19 Response
COVID-19 Response: Ensure that people living with liver disease are not disproportionately impacted by COVID-19 and do not experience unnecessary or discriminatory health care or treatment disruptions
Health Disparities
Health Disparities: Address inequities in the care of people impacted by liver disease
Liver Health Policy
Liver Health Policy: Advance Liver Health is Public Health globally, the U.S. NASH Action Plan, and policies that prevent and address the more than 100 types of liver diseases and related conditions
Liver Health Regulations
Liver Health Regulations: Work with regulators to better incorporate the experiences, perspectives, and needs of liver patients into regulatory decision-making
Engaged Initiatives
Liver Health Research
Liver Health Research: Advocate for funding that ensures meaningful growth of vital liver health research and public health programs
Transplant
Transplant: Urgently respond to the inequities that impact organ transplantation; improve care for transplant patients, and increase the number of available organs
Viral Hepatitis
Viral Hepatitis: Increase support for hepatitis programs and raise awareness of viral hepatitis; advocate for the the elimination of viral hepatitis
Value
Value: Advance health care policies that reflect the unique ability patients have to contribute to the understanding of their condition and treatment management
Patient Access and Reimbursement
Patient Access and Reimbursement: Support policy solutions that curb patients’ health care expenses, and protect access to transformative therapies
Take Action
Co-Sponsor the Liver, Illness, Visibility, Education, and Research (LIVER) Act 2021 (H.R. 5675)
Co-Sponsor the Medical Nutrition Equity Act (H.R. 3783)
Co-Sponsor the Multi-Cancer Early Detection Screening Coverage Act (S. 1873)
Co-Sponsor the Treat & Reduce Obesity Act (S. 596)
Co-Sponsor the Safe Step Act (S. 464)
Policy Highlights
Leading multiple Virtual Liver Advocacy Days and Congressional Briefings that educate policy makers about liver health
Urging regulators to support additional COVID-19 vaccine doses for immunocompromised individuals
Working with the U.S. Congress to reform the Organ Transplant System, advance patient centric legislative packages, and introduce liver specific bills like the LIVER Act, and the NASH Care Act
Externally-Led Patient-Focused Drug Development Meetings
Externally-Led Patient-Focused Drug Development (EL-PFDD) Meetings are held to systematically obtain the patient perspective on specific decisions and their treatments to provide context for regulatory decisions for new drugs. GLI holds EL-PFDD meetings with key partners to promote patients’ perspectives as pharmaceutical solutions for liver diseases are developed.